Patents by Inventor Bo-Jiang Zheng

Bo-Jiang Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
    Patent number: 7429656
    Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: September 30, 2008
    Assignee: The University of Hong Kong
    Inventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng
  • Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
    Patent number: 7361747
    Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: April 22, 2008
    Assignee: The University of Hong Kong
    Inventors: Yi Guan, Bo-Jiang Zheng
  • ISOLATION AND CHARACTERIZATION OF THE PRECURSOR VIRUS OF HUMAN SARS VIRUS: SARS-ASSOCIATED CORONA VIRUS-LIKE VIRUS
    Publication number: 20080069839
    Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.
    Type: Application
    Filed: May 24, 2004
    Publication date: March 20, 2008
    Inventors: Yi Guan, Bo-Jiang Zheng
  • Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
    Publication number: 20060258611
    Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
    Type: Application
    Filed: June 14, 2006
    Publication date: November 16, 2006
    Inventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Lin, Ying Peng
  • Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
    Patent number: 7129223
    Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: October 31, 2006
    Assignee: The University of HongKong
    Inventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng
  • Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
    Publication number: 20050004063
    Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
    Type: Application
    Filed: May 19, 2004
    Publication date: January 6, 2005
    Inventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Lin, Ying Peng